Primary hyperoxaluria

On 20 February 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 354. The active ingredient is oxalobacter formigenes strain HC-1 for treatment of primary hyperoxaluria.